Osteoarthritic (OA) pain represents the second largest segment of the chronic pain market and is expected to grow, driven by an aging population and the increasing prevalence of obesity. However, a comprehensively effective and tolerable analgesic class alternative has not become available for this indication in nearly two decades. A successful launch of a new analgesic requires a deep understanding of current treatment patterns in this highly generic and OTC market. Over the past few years, several new therapies have launched in the OA pain market, providing incremental safety, tolerability, and/or dosing benefits to overcome the drawbacks of the current standards of care—nonsteroidal anti-inflammatory drugs (NSAIDs) and opioid analgesics—but how have agents in these drug classes, particularly brand-only products, fared in this highly generic market?
Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand usage across different lines of therapy using real-world data patient-level claims data, so you can accurately assess your source of business and quantify areas of opportunity for increasing your brand share.
Markets covered: United States.
Real-world data: Longitudinal patient-level claims data analysis.
Key companies: Purdue Pharma, Janssen, Collegium Pharmaceuticals, Horizon Pharma, and Pfizer.
Key drugs: Hysingla ER, Nucynta ER, oxycodone CR (OxyContin, generics), Vimovo, Vivlodex, Xtampza ER, and Zorvolex.
Key analysis provided: